Article Sidebar

PDF
Date Published: 09/10/2022
Abstract Views: 474
Views PDF: 206
DOI: https://doi.org/10.51298/vmj.v518i2.3476
Issue
Vol. 518 No. 2 (2022)
Section
Các bài báo
How to Cite
Lâm Sơn, P. ., Hồng Thăng, V. ., Vinh Quang, B. ., & al., et. (2022). ASSESSMENT OF THE RESULTS OF CHEMORADIOTHERAPY OF STAGE IIB-III NASOPHARYNGEAL CANCER TREATMENT BY WEEKLY CISPLATIN AND MODULATED RADIATION THERAPY. Vietnam Medical Journal, 518(2). https://doi.org/10.51298/vmj.v518i2.3476

ASSESSMENT OF THE RESULTS OF CHEMORADIOTHERAPY OF STAGE IIB-III NASOPHARYNGEAL CANCER TREATMENT BY WEEKLY CISPLATIN AND MODULATED RADIATION THERAPY

Phạm Lâm Sơn1,, Vũ Hồng Thăng1,2, Bùi Vinh Quang2, et al.2,3
1 Vietnam National Cancer Hospita
2 Hanoi Medical University
3 Vietnam National Cancer Hospital

Main Article Content

Abstract

Objective: The study aimed to evaluate the results of the combination chemoradiotherapy regimen for stage IIB-III nasopharyngeal cancer with a weekly dose of cisplatin and Intensity Modulated Radiation Therapy. Subjects and methods: An uncontrolled clinical intervention study on 68 stage IIB-III nasopharyngeal cancer patients, these patients received Intensity Modulated Radiation Therapy in combination with cisplatin 40mg/m2 body skin weekly for 6 weeks of radiotherapy, with or without adjuvant chemotherapy added. The treatment period is from January 2018 to April 2022 at K Hospital. Results: The rate of complete and partial response to treatment at 1 month and 3 months after the end of chemoradiotherapy was 86.7%, respectively; 95% and 13.3; 5%, there were no cases of unresponsive or progressive disease. Mean overall survival time: 34.41 ± 9.15 months. Overall survival: 97% at 12 months, 89.7% at 24 months and 84.1% at 36 months. The median disease-free survival time was 33.04 ± 10.74 months, disease-free survival: 12 months was 91.2%, 24 months was 85.3% and 36 months was 82.3%. Conclusion: The response to weekly cisplatin chemotherapy and Modulated Radiation Therapy was quite good, the overall survival and disease-free survival were both higher than those of traditional treatment regimens.

Article Details

Keywords

nasopharyngeal cancer, chemoradiotherapy, Modulated Radiation Therapy, respond to treatment, life time

References

1. Trần Thị Kim Phượng. Đánh giá kết quả hóa xạ trị đồng thời trong ung thư vòm họng giai đoạn II tại bệnh viện K. in Luận án tiến sĩ Y học, Trường Đại Học Y Hà Nội 1–120 (2018).
2. Đặng Huy Quốc Thịnh. Hóa xạ trị đồng thời carcinoma vòm hầu giai đoạn tiến xa tại chỗ- tại vùng. in Luận án tiến sĩ Y học, Trường Đại học Y Dược 1–128 (2012).
3. Ngô Thanh Tùng. Nghiên cứu kết quả thử nghiệm lâm sàng pha II hóa xạ trị bệnh ung thư vòm họng giai doạn II- IVB có di căn hạch N2,3 chưa di căn xa. Tạp trí ung thư học Việt Nam 2, 107 (2008).
4. Al-sarraf, B. M. et al. Randomized Intergroup Study 0099. Society 16, 1310–1317 (1998).
5. Chen, L. et al. Concurrent chemoradiotherapy plus adjuvant chemotherapy versus concurrent chemoradiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 3 multicentre randomised controlled trial. Lancet. Oncol. 13, 163–171 (2012).
6. International Agency for Research on Cancer - World Health Organization. GLOBOCAN 2020: Viet Nam - Global Cancer Observatory. https://gco.iarc.fr/ today/data/factsheets/ populations/704-viet-nam-fact-sheets.pdf. Published December, 2020. Accessed December 27, 202
7. Lin, J. C., Jan, J. S. & Hsu, C. Y. Pilot study of concurrent chemotherapy and radiotherapy for stage IV nasopharyngeal cancer. Am. J. Clin. Oncol. 20, 6–10 (1997).
8. Wee, J. et al. Randomized trial of radiotherapy versus concurrent chemoradiotherapy followed by adjuvant chemotherapy in patients with American Joint Committee on Cancer/International Union against cancer stage III and IV nasopharyngeal cancer of the endemic variety. J. Clin. Oncol. 23, 6730–6738 (2005).